Jan 29 (Reuters) - Eurofins Scientific SE EUFI.PA:
DELIVERS FY 2025 OBJECTIVES WITH A 24% EPS GROWTH, ACCELERATING ORGANIC REVENUE GROWTH, MARGIN EXPANSION, AND HIGHER FREE CASH FLOW AND CONFIRMS ITS 2027 OBJECTIVES
BASIC EPS8 GREW 24% TO EUR 2.31 IN 2025 VERSUS EUR 1.87 IN 2024
FY REVENUE AT EUR 6,756 MILLION
FY EBITDA EUR 1,641 MILLION
NET DEBT AT THE END OF DEC 2025 EUR 3,641 MILLION
FY FCF TO FIRM BEFORE INVESTMENT IN OWNED SITES AT EUR 1,071 MILLION
FOR FY 2026 TARGETS MID-SINGLE-DIGIT ORGANIC GROWTH AND POTENTIAL ANNUALISED REVENUES FROM ACQUISITIONS OF EUR 250 MILLION, CONSOLIDATED AT MID-YEAR
FOR FY 2026 ADJUSTED EBITDA MARGIN EXPECTED TO SHOW FURTHER PROGRESS TOWARDS 2027 OBJECTIVE, WITH IMPROVEMENT ABOVE FY 2025 MARGIN
CONFIRMS ITS OBJECTIVES FOR MID-TERM (POST-2027) AND FOR FY 2027
Source text: ID: nBwVcP05a
Further company coverage: EUFI.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))